-

05:43:45 PM

VCEL Stock News

VCEL - Vericel Corp

01/10/23 7:55 AM

Nasdaq : VCEL

earnings

Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program

Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately 24% MACI Arthroscopic Commercial Launch Now Planned for 2024 CAMBRIDGE, Mass., Jan. 10, 2023

RHEA-AI

positive

01/05/23 9:00 AM

Nasdaq : VCEL

management

Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Wotton serves on the Board of Directors of Vericel Corporation and Cynata Therapeutics and is a Founder of Avenge Bio. Dr. Wotton was recently named as a“ Top 100 Innovation CEO” by World Biz Magazine and won the...

RHEA-AI

neutral

01/04/23 8:34 AM

Nasdaq : VCEL

conferences

Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41 st Annual J.P. Morgan Healthcare Conference.

RHEA-AI

neutral

12/29/22 1:45 PM

Nasdaq : VCEL

fda approval

Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults

Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating significantly higher incidence of complete eschar removal in patients treated with NexoBrid compared to placebo

RHEA-AI

positive

11/10/22 9:00 AM

Nasdaq : VCEL

conferences

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital

RHEA-AI

neutral

11/09/22 7:55 AM

Nasdaq : VCEL

earnings

Vericel Reports Third Quarter 2022 Financial Results

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn

RHEA-AI

neutral

10/26/22 8:30 AM

Nasdaq : VCEL

conferencesearnings

Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel’s

RHEA-AI

neutral

09/22/22 8:30 AM

Nasdaq : VCEL

conferences

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference.

RHEA-AI

neutral

09/06/22 8:30 AM

Nasdaq : VCEL

conferences

Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor

RHEA-AI

neutral

08/03/22 7:55 AM

Nasdaq : VCEL

earnings

Vericel Reports Second Quarter 2022 Financial Results

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care

RHEA-AI

neutral

1 2 3 4 5 6 Next

VCEL Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitevcel.com
CeoDominick Colangelo
Security nameVericel Corp
Issue typecs
SectorManufacturing
Sic code2836
Employees281
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address64 Sidney St
StateMassachusetts
CityCambridge
Zip02139-4170
CountryUS
Phone17349305555

About Vericel Corp

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.